Drug Trial Radar · NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Feb 23, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Adrienne G. WaksAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Verastem, Inc.; Eli Lilly and Company
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Conditions
- Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
VS-6766Drug
Taken Orally
AbemaciclibDrug
Taken Orally
FulvestrantDrug
Administered by intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Maximum tolerated dose (MTD)Time frame: 4 Weeks up to 2 years
- Phase 1 Recommended Phase II Dose (RP2D)Time frame: 4 Weeks up to 2 years
- Phase 2 Clinical benefit rate (CBR)Time frame: 6 months up to 3 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Withdrawn
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institite
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.